“…However, they suffer from the drawback of not being compatible with the human immune system due to their heterologous nature (Laustsen et al, 2016a), and from having a low content of therapeutically active antibodies, particularly against small venom components with low immunogenicity and high toxicity (Laustsen et al, 2017;Leong et al, 2015;Tan et al, 2015Tan et al, , 2016. In recent time, venomics and antivenomics approaches have helped build a greater understanding of the antigenicity of different venom components, which may provide guidance on how to design immunization mixtures that give rise to venom-paraspecific antibody responses in production animals (Calvete et al, 2014(Calvete et al, , 2009Lomonte and Calvete, 2017). Such knowledge creates a foundation for improving the neutralization potential of antivenoms against toxin subfamilies with low immunogenicity, such…”